OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold.
作者信息
Gragnano Felice, Capolongo Antonio, Galli Mattia, Calabrò Paolo
机构信息
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta 81100, Italy.
Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta 81100, Italy.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):575-577. doi: 10.1093/ehjcvp/pvae065.
Abstract
摘要
相似文献
1
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold.大洋洲房颤试验：XI因子抑制剂在房颤治疗方面的变革暂停。
Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):575-577. doi: 10.1093/ehjcvp/pvae065.
2
What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?对于心房颤动患者，凝血因子XIa抑制剂的未来地位如何？
Eur Cardiol. 2024 Jul 1;19:e10. doi: 10.15420/ecr.2023.50. eCollection 2024.
3
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).不同类型心房颤动患者的卒中与死亡风险：来自 ENGAGE AF-TIMI 48 试验（新型 Xa 因子抗凝在心房颤动-心肌梗死溶栓 48 中的疗效）的结果。
Circ Arrhythm Electrophysiol. 2017 Jan;10(1). doi: 10.1161/CIRCEP.116.004267.
4
OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?OCEANIC-AF研究以及与阿哌沙班相比，阿孙西泮在高危房颤患者中的疗效较差：我们是否已走到了XIa因子抑制剂的尽头？
Am Heart J Plus. 2024 Sep 21;46:100464. doi: 10.1016/j.ahjo.2024.100464. eCollection 2024 Oct.
5
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.肾功能障碍作为非瓣膜性心房颤动患者中风和全身性栓塞的预测因子：ROCKET AF（利伐沙班每日一次，口服，直接 Xa 因子抑制与维生素 K 拮抗剂预防中风和房颤试验）和 ATRIA（心房颤动抗凝和危险因素）研究队列中 R(2)CHADS(2)指数的验证。
Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.
6
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.亚洲房颤患者依不同剂量标准（ROCKET AF 或 J-ROCKET AF 试验）使用利伐沙班的比较。
J Am Heart Assoc. 2019 Nov 5;8(21):e013053. doi: 10.1161/JAHA.119.013053. Epub 2019 Oct 18.
7
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?XI 因子抑制剂会取代当前的抗凝剂用于房颤卒中预防吗？
Curr Cardiol Rep. 2024 Sep;26(9):911-917. doi: 10.1007/s11886-024-02100-y. Epub 2024 Jul 23.
8
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).地高辛在伴有不良心血管结局的心房颤动患者中的应用：利伐沙班每日一次口服直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞的临床试验（ROCKET AF）的回顾性分析。
Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.
9
Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP - A narrative review.心房颤动、血栓栓塞风险与利钠肽的潜在作用，聚焦于脑钠肽和N末端脑钠肽原——一篇叙述性综述
Int J Cardiol Heart Vasc. 2022 Oct 10;43:101132. doi: 10.1016/j.ijcha.2022.101132. eCollection 2022 Dec.
10
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.赞图斯：利伐沙班预防心房颤动患者中风的非干预性研究的原理与设计
Vasc Health Risk Manag. 2014 Jul 17;10:425-34. doi: 10.2147/VHRM.S63298. eCollection 2014.
引用本文的文献
1
Bleeding and thrombosis.出血与血栓形成。
Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):211-212. doi: 10.1093/ehjcvp/pvaf017.
2
AZALEA-TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain.杜鹃花-TIMI 71试验：在心房颤动中，与利伐沙班相比，阿贝西单抗导致的出血更少，但预防中风的效果尚不确定。
Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):213-214. doi: 10.1093/ehjcvp/pvaf008.
3
Efficacy and safety of ticagrelor monotherapy following a brief DAPT vs. prolonged 12-month DAPT in ACS patients post-PCI: a meta-analysis of RCTs.替格瑞洛单药治疗与 PCI 后 ACS 患者短程 DAPT（<1 个月）与长程 12 个月 DAPT 的疗效和安全性：RCT 的荟萃分析。
Eur J Clin Pharmacol. 2024 Dec;80(12):1871-1882. doi: 10.1007/s00228-024-03747-w. Epub 2024 Sep 12.
本文引用的文献
1
Asundexian versus Apixaban in Patients with Atrial Fibrillation.阿孙地昔与阿哌沙班用于心房颤动患者的比较
N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1.
2
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients.寻找圣杯：患者血栓形成风险与出血风险之间的平衡。
Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):367-369. doi: 10.1093/ehjcvp/pvae052.
3
Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation.口服抗凝剂在房颤患者中的疗效和安全性与肾功能相关。
Eur Heart J Cardiovasc Pharmacother. 2024 May 4;10(3):210-218. doi: 10.1093/ehjcvp/pvae016.
4
Pharmacological and clinical appraisal of factor XI inhibitor drugs.因子 XI 抑制剂药物的药理学和临床评估。
Eur Heart J Cardiovasc Pharmacother. 2024 May 4;10(3):245-258. doi: 10.1093/ehjcvp/pvae002.
5
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation.直接口服抗凝剂与华法林在衰弱的心房颤动患者中的有效性和安全性。
Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):137-146. doi: 10.1093/ehjcvp/pvad091.
6
Factor XIa inhibitors: collecting the clinical evidence.凝血因子XIa抑制剂：收集临床证据。
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):5-6. doi: 10.1093/ehjcvp/pvad076.
7
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.极低剂量与常规剂量非维生素K拮抗剂口服抗凝剂治疗出血风险增加的老年房颤患者的临床结局：一项全国性队列研究
Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14;9(8):681-691. doi: 10.1093/ehjcvp/pvad058.
8
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.2022年的新型药理学药物与心血管药物治疗新策略
Eur Heart J Cardiovasc Pharmacother. 2023 May 11;9(4):353-70. doi: 10.1093/ehjcvp/pvad034.
9
The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway.心房颤动的神经认知影响：ABC 途径的益处。
Eur Heart J Cardiovasc Pharmacother. 2023 Jul 29;9(5):413-420. doi: 10.1093/ehjcvp/pvad021.
10
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.早期临床试验中的因子 XI 抑制剂：荟萃分析。
Thromb Haemost. 2023 Jun;123(6):576-584. doi: 10.1055/a-2043-0346. Epub 2023 Feb 25.
Zotero 插件